Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details


  • Main Hospital

    Washington, District of Columbia 20010
    1-888-884-BEAR (2327)

Education & Training

  • MPH, 1994
    George Washington University
  • Fellowship Program, Pediatric Infectious Diseases, 1982
    National Institutes of Health
  • Residency Program, Pediatrics, 1979
    University of Massachusetts Medical Ctr
  • Internship Program, Flexible Internship, 1976
    Boston University Hospital
  • MBBS, 1974
    Benares Hindu University
  • BS, Pre-Med, 1969
    Benares Hindu University

Board Certifications

  • American Board of Pediatrics
  • American Board of Pediatrics/Infectious Diseases

National Provider ID: 1619054095


Nalini Singh, M.D., M.P.H., is in the Division of Infectious Disease at Children's National Health System. Dr. Singh’s research interests include the prevention of healthcare-associated infections, molecular diagnostics related to multi-drug resistant organisms and global health initiatives related to infection prevention. She is an invited speaker to national and international conferences and is a Fulbright Scholar.

Dr. Singh was appointed to membership of the Centers for Disease Control and Prevention’s Healthcare Infection Control Practices Advisory Committee by the Secretary of Health and Human Services and served on the committee from 2003-2008. On this committee, she helped develop guidelines for the prevention of transmission of multi-drug resistant organisms and in the review of the compendium on the prevention of healthcare-associated infections. She is a preceptor and advisor for candidates in the Masters in Public Health program and mentors medical students, fellows and junior faculty. She is chair of Children's Infection Control Committee.

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

Outside Interests

  • Pfizer 
  • World Health Organization (WHO)

Changing Epidemiology of Clostridium Difficile-Associated Disease in Children

(2007) Infection Control Hospital Epidemiology

Control of Vancomycin Resistant Enterococci in the Neonatal Intensive Care Unit

(2005) Infection Control Hospital Epidemiology

Epidemiology of Clostridium Difficile in Infants Younger than Two Years of Age

(2008) Society of Healthcare Epidemiology

Epidemiology of Infection and Colonization with Vancomycin-Resistant Enterococci and Frequency of Co-Colonization with Methicillin-Resistant Staphylococcus Aureus in Children

(2007) Infection Control Hospital Epidemiology

Epidemiology of Invasive Group A Streptococcus Infections in Children Society of Pediatric Research

(2008) Pediatric Academic Societies

Molecular and Descriptive Epidemiology of Multi-Drug Resistant Enterobacteriaceae in Hospitalized Infants

(2008) Infection Control Hospital Epidemiology

Society of Healthcare Epidemiology

(2008) Clinical and economic impact of Methicillin-resistant Staphylococcus aureus on patients in the neonatal intensive care unit

Society of Pediatric Research

(2008) The Increasing Incidence of Community-Associated Methicillin Resistant Staphylococcus aureus (MRSA) in Hospitalized Neonates

St Jude's Pediatric Society Meeting

(2008) The Evolution of Methicillin-resistant Staphylococcus aureus in Neonates